Europe Renews Push to Slash Global Tariffs on Medical Goods
(Bloomberg) --
The European Union is pressing for a global deal to eliminate tariffs on pharmaceuticals and medical supplies in an effort to guard against the kind of supply-chain shock triggered by the coronavirus pandemic.
The European Commission, the EU's executive arm, outlined options for encouraging worldwide commerce in health-care goods in a policy paper due to be discussed by the 27-nation bloc's trade ministers in a June 9 video conference.
Europe Seeks to Abolish Tariffs in $597 Billion Medical Trade
The goal would be to end customs duties on drugs including antibiotics, penicillins and vaccines and on equipment such as masks, gloves and gowns. The initiative would also aim to give countries less room during health crises to curb international trade in such goods through, for example, export restrictions.
“Facilitating international trade in health-care products contributes to making supply chains more resilient and diversified,” the commission said in the internal paper obtained by Bloomberg News. “International trading opportunities also incentivize greater production in the sector, as companies can serve the global as opposed to only the domestic market.”
The commission proposes that the EU seeks an international agreement open to all World Trade Organization Members for participation, for the duties cut. “Tariff elimination would be conditioned on reciprocity among countries representing a significant share of world trade in the sector,” according to the memo.
Europe Suspends Import Duties on Medical Gear to Fight Pandemic
As countries around the world emerge from lockdowns triggered by the pandemic, the EU wants to use trade as a tool to help revive devastated economies and prevent commercial barriers from re-emerging during future health scares.
Global market-opening measures for health-care goods would also help the least-developed nations cope with future crises, according to the commission.
The EU, the world's most lucrative single market, has itself faced criticism for temporarily requiring an authorization this year for the sale outside the bloc of personal protective equipment needed to fight the coronavirus. The EU let the export controls, introduced in mid-March, lapse last week.
©2020 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.